genome-wide
No description yet: the sentence for this tag has not been written. 3 records carry it: 3 biomarkers.
Related tags
3 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
ctDNA MRD positivity (molecular residual disease after curative treatment) Genome-wide readout A ctDNA MRD test looks for the tumour's own mutations in blood after surgery. Detection predicts relapse months before scans, and in 2026 the FDA approved Signatera as the companion test selecting bladder cancer patients for adjuvant atezolizumab. | Bladder & urothelial cancer, Colorectal cancer, Triple-negative breast cancer | none | biomarker, ctdna | ||
HRD-positive (genomic instability score) BRCA1, BRCA2 HRD-positive means the tumour's genome carries the scars of failed double-strand break repair (or a BRCA mutation), measured as a genomic instability score. In ovarian cancer it selects niraparib, and olaparib with bevacizumab, as first-line maintenance. | Ovarian cancer, High-grade serous ovarian cancer | none | biomarker, brca | ||
TMB-high (tumour mutational burden >= 10 mutations per megabase) Genome-wide readout TMB counts how many mutations a tumour carries per million DNA letters. Ten or more, measured by FoundationOne CDx, allows pembrolizumab for almost any solid tumour after other treatment has failed. | Metastatic cancer, Non-small-cell lung cancer, Melanoma | none | biomarker |